[Clostridium difficile colitis].

Area of Science:

• Microbiology
• Infectious Diseases
• Gastroenterology

Background:

• Clostridioides difficile is an anaerobic, spore-forming enteropathogen causing a spectrum of gastrointestinal illnesses.
• Risk factors for C. difficile infection (CDI) include advanced age, hospitalization, and recent antibiotic use.
• The emergence of a hypervirulent 027/NAP/BI strain has led to increased CDI severity and mortality globally.

Purpose of the Study:

• To outline the clinical spectrum and risk factors associated with Clostridioides difficile infection.
• To describe the primary virulence factors, including toxins A and B.
• To review current therapeutic strategies and infection control recommendations for CDI.

Main Methods:

• Literature review of C. difficile epidemiology, pathogenesis, and clinical management.
• Analysis of risk factors, including patient demographics and healthcare exposures.
• Summary of antibiotic treatment options and antimicrobial stewardship principles.

Main Results:

• CDI presents with symptoms ranging from mild diarrhea to life-threatening conditions like toxic megacolon.
• Toxins A (TcdA) and B (TcdB) are key virulence factors contributing to disease severity.
• The hypervirulent 027/NAP/BI strain is associated with increased outbreaks and worse patient outcomes.

Conclusions:

• Effective CDI management requires tailored antibiotic therapy based on disease severity, utilizing metronidazole, vancomycin, or fidaxomicin.
• Antimicrobial stewardship and contact precautions are crucial for controlling CDI transmission and preventing outbreaks.